| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | C1 inhibitor produced in milk of transgenic mammals | JP2014075150 | 2014-04-01 | JP2014121337A | 2014-07-03 | NUIJENS JOHANNES HENRICUS; VAN VEEN HENRICUS ANTONIUS; PIEPER FRANK R; HEUS JORIS JAN |
| PROBLEM TO BE SOLVED: To provide transgenic nonhuman mammals expressing C1 inhibitor in their milk.SOLUTION: The invention provides transgenic nonhuman mammals expressing C1 inhibitor in their milk. The C1 inhibitor is useful in treating patients with hereditary angioedema or patients requiring immunosuppression. The transgenic nonhuman mammals of the invention have a transgene comprising a recombinant DNA segment encoding a C1 inhibitor operably linked to at least one regulatory sequence effective to promote expression of the DNA segment in mammary gland cells, and a segment functionally encoding signal peptide in mammary secretory cells. | ||||||
| 2 | Lysosomal proteins produced in the milk of transgenic animals | JP50811397 | 1996-07-31 | JP2000501602A | 2000-02-15 | ピーペル，フランク，アール．; デル プレグ，アンス，ティー ファン; フェルビート，マーティン，ピーエイチ．; リューザー，アーノルド，ジェイ．，ジェイ． |
| (57)【要約】 本発明は、ミルク中にホスホリル化されたリソソーム性蛋白質を生成するトランスジェニック非ヒト哺乳動物およびそれを生成する方法を提供する。 ホスホリル化は、マンノース側鎖残基の６′位で生じる。 ミルクからのリソソーム性蛋白質を精製し、蛋白質を、酵素置換療法で使用するための薬剤組成物に加える方法がまた提供される。 | ||||||
| 3 | Marker assisted selection of bovine for improved milk production using diacylglycerol acyltransferase gene DGAT1 | US10415620 | 2001-10-31 | US07537888B2 | 2009-05-26 | Michel Alphonse Julien Georges; Wouter Herman Robert Coppieters; Bernard Marie-Josee Jean Grisart; Russell Grant Snell; Suzanne Jean Reid; Christine Ann Ford; Richard John Spelman |
| The present invention provides a method of genotyping bovine for improved milk production traits by determining the DGAT1 genotypic state of said bovine, wherein the DGAT1 gene and polymorphisms within said gene have been found to be associated with such improved milk production traits. | ||||||
| 4 | Mammals expressing IGF-1 and alpha-lactalbumin in their milk | US10676566 | 2003-09-30 | US07169963B2 | 2007-01-30 | Matthew B. Wheeler; Sharon M. Donovan; Gregory T. Bleck; Marcia Monaco-Siegel |
| The present invention relates to animals that express exogenous growth factors in their milk, and in particular to pigs that express exogenous IGF-I in their milk. The present invention also relates to methods for increasing piglet weight gain and intestinal lactase activity. The present invention thus provides a method of facilitating piglet development and decreasing piglet mortality. | ||||||
| 5 | Mutated recombinant collagens | US10720831 | 2003-11-24 | US20050192428A1 | 2005-09-01 | Richard Berg; Paul Toman; Donald Wallace |
| The invention provides recombinant procollagen chains having a natural collagen chain separated from one or two propeptide by one or two non-natural site-specific proteolytic agent (e.g., protease) recognition sites. A wide variety of propeptides and site-specific proteolytic agent recognition sites may be used: the selection of particular site-specific proteolytic agent/recognition site pairs is based on the conformation of the resulting procollagen, the availability of the site-specific proteolytic agent, the compatibility of the proteolysis with production of mature collagen, among other factors. Recombinant collagens chains are produced by contacting the subject recombinant procollagen chains with the appropriate site-specific proteolytic agents. Nucleic acids encoding the subject procollagen chains operably linked to transcription regulatory elements are used in vectors and cells for the production of recombinant collagen. Such collagen is used in tissue and cell cultureware and therapeutically, such as in biodegradable surgical materials and for tissue augmentation. | ||||||
| 6 | Method for reducing or preventing modification of a polypeptide in solution | US10302592 | 2002-11-22 | US20040101939A1 | 2004-05-27 | Ling C. Santora; Krista H. Stanley |
| The present invention encompasses a novel approach to reduce or to prevent modification of polypeptides in solution and to polypeptides obtained by such methods. Specifically, the invention relates to a method for reducing or preventing modification of polypeptides in milk, particularly milk obtained from a transgenic animal, and to polypeptides isolated using such methods. | ||||||
| 7 | Marker assisted selection of bovine for improved milk production using diacylglycerol acyltransferase gene dgat1 | US10415620 | 2003-11-13 | US20040076977A1 | 2004-04-22 | Michel Alphonse Julien Georges; Wonter Herman Robert Coppieters; Bernard Marie-Josee Jean Grisart; Russell Grant Shell; Suzanne Jean Reid; Christine Ann Ford; Richard John Spelman |
| The present invention provides a method of genotyping bovine for improved milk production traits by determining the DGAT1 genotypic state of said bovine, wherein the DGAT1 gene and polymorphisms within said gene have been found to be associated with such improved milk production traits. | ||||||
| 8 | C1 Inhibitor produced in the milk of transgenic mammals | US10181704 | 2002-07-17 | US20030140358A1 | 2003-07-24 | Johannes Henricus Nuijens; Henricus Antonius Van Veen; Frank Robert Pieper; Jonis Jan Heus |
| The invention provides transgenic nonhuman mammals expressing C1 inhibitor in their milk. The C1 inhibitor is useful in treating patients with hereditary angioedema or patients requiring immunosuppression. | ||||||
| 9 | Compositions and methods for treating enzyme deficiency | US10014511 | 2001-12-14 | US20020157123A1 | 2002-10-24 | Arnold J. Reuser; Ans T. Van der Ploeg; Martin Ph. Verbeet |
| The invention provides transgenic nonhuman mammals producing phosphorylated lysosomal proteins in their milk, methods of generating the same, pharmaceutical compositions for use in enzyme replacement therapy, and methods of treating Pompe's disease using human acid alpha glucosidase. | ||||||
| 10 | Animals expressing exogenous IGF-I in their milk | US09930377 | 2001-08-15 | US20020144296A1 | 2002-10-03 | Matthew B. Wheeler; Sharon M. Donovan; Gregory T. Bleck; Marcia Monaco-Seigel |
| The present invention relates to animals that express exogenous growth factors in their milk, and in particular to pigs that express exogenous IGF-I in their milk. The present invention also relates to methods for increasing piglet weight gain and intestinal lactase activity. The present invention thus provides a method of facilitating piglet development and decreasing piglet mortality. | ||||||
| 11 | Targeted synthesis of protein in mammary gland of a non-human transgenic mammal | US186836 | 1994-01-25 | US5994616A | 1999-11-30 | Jeffrey M. Rosen |
| Described are methods of targeting specific genes or DNA sequences encoding biologically active proteins to the mammary gland such that the DNA sequence is expressed in the mammary gland and the protein is secreted into the milk of the mammal. Also described is the production of transgenic nonhuman mammals whose germ line comprises a DNA gene complex containing a casein promoter, a casein enhancer, a DNA sequence which encodes a signal peptide and a DNA sequence encoding a biologically active protein. The milk containing the biologically active protein or the biologically active protein itself can be used in the making of diary products. | ||||||
| 12 | C1 inhibitor produced in milk of transgenic mammal | JP2011270236 | 2011-12-09 | JP2012050465A | 2012-03-15 | NUIJENS JOHANNES HENRICUS; VAN VEEN HENRICUS ANTONIUS; PIEPER FRANK R; HEUS JORIS JAN |
| PROBLEM TO BE SOLVED: To provide a transgenic nonhuman mammals expressing C1 inhibitor in their milk.SOLUTION: The transgenic nonhuman mammals expressing C1 inhibitor in their milk are provided. The C1 inhibitor is useful in treating patients with hereditary angioedema or patients requiring immunosuppression. The transgenic nonhuman mammals have a transgene comprising a recombinant DNA segment encoding a C1 inhibitor operably linked to at least one regulatory sequence effective to promote expression of the DNA segment in mammary gland cells and a segment encoding signal peptide functionally in mammary secretory cells. | ||||||
| 13 | c1 inhibitor produced in the milk of transgenic mammals | JP2001557910 | 2001-01-31 | JP2003521914A | 2003-07-22 | ヨハネス ヘンリクス ノイエンス，; フランク エール． ピーピル，; ヨリス ヤン ヒュース，; フェーン， ヘンリクス アントニウス ファン |
| (57)【要約】 本発明は、その乳汁中にＣ１インヒビターを発現するトランスジェニック非ヒト哺乳動物を提供する。 Ｃ１インヒビターは、遺伝性血管性浮腫を有する患者または免疫抑制を必要とする患者を処置するのに有用である。 本研究の１つの局面において、非ヒト哺乳動物は、この哺乳動物に対して異種のＣ１インヒビターをコードするＤＮＡセグメントであって、この哺乳動物の乳腺細胞におけるこのＤＮＡセグメントの発現を促進させるのに効果的な少なくとも１つの調節配列に対して作動可能に連結されている、ＤＮＡセグメント、およびこの哺乳動物の乳房細胞において機能するシグナルペプチドをコードするセグメント、を含み；ここで、このＣ１インヒビターをコードするＤＮＡセグメントが、この哺乳動物の成体形またはその雌の子孫の乳腺細胞において発現されて、この非ヒト哺乳動物の乳汁中にＣ１インヒビターを産生し得る、非ヒト哺乳動物を提供する。 | ||||||
| 14 | dna sequences in the protein to be issued in the mammary gland for the efficient secretion | JP3493388 | 1988-02-17 | JP2863789B2 | 1999-03-03 | JEFURII EMU ROOZEN |
| Described is a method of targeting specific genes to the mammary gland which results in the efficient synthesis and secretion of biologically important molecules. Further, there is described as a composition of matter, a transgenic mammal having the ability to reproduce itself and being suitable for the secretion of biologically active agents into its milk. Additionally there is disclosed as a composition of matter, recombinant DNA gene complexes designed to integrate into a mammalian genome and to synthesize and secrete biological active agents into the milk. Furthermore methods of producing and using altered milk are disclosed. | ||||||
| 15 | Preparation of human recombinant collagen in the milk of transgenic animals | JP51719494 | 1994-01-19 | JPH08506016A | 1996-07-02 | エー． バーグ、リチャード |
| (57)【要約】 通常にヒトコラーゲン又はヒトプロコラーゲンを製造しない細胞内におけるこれらの蛋白質の製造は、非ヒト哺乳動物の乳腺に適合した発現系を構築することにより達成される。 例えば、組換えヒトプロコラーゲン又は組換えヒトコラーゲンを含むミルクを製造する能力を有するトランスジェニック非ヒト哺乳動物を得るために、発現系は、受精した卵母細胞内に顕微注射され、代理母内に再植え付けされ、妊娠期間終了まで養われ得る。 この方法で製造されたヒトプロコラーゲン又はヒトコラーゲンは、他のヒト又は非ヒトコラーゲンの混入していない単一の型のコラーゲンから構成され得る。 | ||||||
| 16 | Dna sequence in protein issued to mammary gland for efficient secretion | JP3493388 | 1988-02-17 | JPS63309192A | 1988-12-16 | JIEFURII EMU ROOZEN |
| Described is a method of targeting specific genes to the mammary gland which results in the efficient synthesis and secretion of biologically important molecules. Further, there is described as a composition of matter, a transgenic mammal having the ability to reproduce itself and being suitable for the secretion of biologically active agents into its milk. Additionally there is disclosed as a composition of matter, recombinant DNA gene complexes designed to integrate into a mammalian genome and to synthesize and secrete biological active agents into the milk. Furthermore methods of producing and using altered milk are disclosed. | ||||||
| 17 | MARKER ASSISTED SELECTION OF BOVINE FOR IMPROVED MILK PRODUCTION USING DIACYLGLYCEROL ACYLTRANSFERASE GENE DGAT1 | EP01992795.3 | 2001-10-31 | EP1330552B1 | 2007-01-24 | Georges, Michel Alphonse Julien; Coppieters, Wouter Herman Robert; Grisart, Bernard Marie-Josee Jean; Snell, Russell Grant; Reid, Suzanne Jean; Ford, Christine Ann; Spelman, Richard John |
| The present invention provides a method of genotyping bovine for improved milk production traits by determining the DGAT1 genotypic state of said bovine, wherein the DGAT1 gene and polymorphisms within said gene have been found to be associated with such improved milk production traits. | ||||||
| 18 | Mutated recombinant collagens | EP95108307.0 | 1995-05-30 | EP0699752B1 | 2003-09-24 | Berg, Richard A.; Toman, Paul David; Wallace, Donald G. |
| 19 | DNA sequences to target proteins to the mammary gland for efficient secretion | EP97203192.6 | 1988-02-10 | EP0832981A1 | 1998-04-01 | Rosen, Jeffrey M. |
The invention provides the use of an enhancer sequence in effecting targeted mammary gland expression in a transgenic non-human mammal of a coding sequence derived from a gene coding for a biologically active agent, said enhancer sequence being employed, together with said coding sequence, in the form of a recombinant DNA gene complex incorporated into the germ line of said mammal. |
||||||
| 20 | Mutated recombinant collagens | EP95108307.0 | 1995-05-30 | EP0699752A2 | 1996-03-06 | Berg, Richard A.; Toman, Paul David; Wallace, Donald G. |
The invention provides recombinant procollagen chains having a natural collagen chain separated from one or two propeptides by one or two non-natural site-specific proteolytic agent (e.g., protease) recognition sites. A wide variety of propeptides and site-specific proteolytic agent recognition sites may be used: the selection of particular site-specific proteolytic agent/recognition site pairs is based on the conformation of the resulting procollagen, the availability of the site-specific proteolytic agent, the compatibility of the proteolysis with production of mature collagen, among other factors. Recombinant collagens chains are produced by contacting the subject recombinant procollagen chains with the appropriate site-specific proteolytic agents. Nucleic acids encoding the subject procollagen chains operably linked to transcription regulatory elements are used in vectors and cells for the production of recombinant collagen. Such collagen is used in tissue and cell cultureware and therapeutically, such as in biodegradable surgical materials and for tissue augmentation. |
||||||
QQ群二维码
意见反馈
意见反馈